Intermediate-acting insulin (NPH): Class Overview and Comparison
Quick answer: Intermediate-acting insulin (NPH) are a class of medicines used for specific therapeutic indications. iMedic covers 8 intermediate-acting insulin (nph) substances. Below is a comparison table linking to detailed pages for each.
Intermediate-acting insulin (NPH) on iMedic (8 substances)
| Substance | Primary indications | Mechanism | Common dose |
|---|---|---|---|
| Insulatard | Type 1 diabetes mellitus, Type 2 diabetes mellitus | Isophane (NPH) human insulin binds insulin receptors to lower blood glucose with | Individualized; typically 0.3-1 IU/kg/day SC |
| Insulatard Innolet | Type 1 diabetes mellitus, Type 2 diabetes mellitus | Isophane (NPH) human insulin providing intermediate-acting glycemic control by b | Individualized; typically 0.3-1.0 IU/kg/day subcutaneously |
| Insuman Basal | Type 1 diabetes mellitus, Type 2 diabetes mellitus | Isophane (NPH) human insulin providing intermediate-acting glycemic control via | Individualized; typically 0.3-1.0 IU/kg/day subcutaneously |
| Insuman Basal Solostar | Type 1 diabetes mellitus, Type 2 diabetes mellitus | Isophane (NPH) human insulin in prefilled SoloStar pen providing intermediate-ac | Individualized; typically 0.3-1.0 IU/kg/day subcutaneously |
| Protaphane | Type 1 diabetes mellitus, Type 2 diabetes mellitus | Isophane (NPH) human insulin providing intermediate-duration glycemic control vi | Individualized (typically 0.3-0.7 IU/kg/day) |
| Protaphane Flexpen | Type 1 diabetes mellitus, Type 2 diabetes mellitus | Isophane human insulin in prefilled FlexPen device for intermediate-duration gly | Individualized (typically 0.3-0.7 IU/kg/day) |
| Protaphane Innolet | Type 1 diabetes mellitus, Type 2 diabetes mellitus | Isophane human insulin in prefilled InnoLet device for intermediate-duration gly | Individualized (typically 0.3-0.7 IU/kg/day) |
| Protaphane Penfill | Type 1 diabetes mellitus, Type 2 diabetes mellitus | Isophane human insulin in Penfill cartridge for intermediate-duration glycemic c | Individualized (typically 0.3-0.7 IU/kg/day) |
About Intermediate-acting insulin (NPH)
Intermediate-acting insulin (NPH) share a common mechanism of action and clinical use. Specific dosing, side effects, contraindications, and drug interactions vary between individual substances within the class. Click any substance above for full prescribing information and patient guidance.
Common considerations across the class
- Indication-specific selection: Different members may be preferred for different conditions or patient populations
- Dose equivalence: Members of the same class are not always interchangeable on a 1:1 dose basis
- Drug interactions: Class members often share interaction profiles (e.g., CYP enzyme effects) but individual variation matters
- Side effects: Some side effects are class-wide; others are substance-specific
- Contraindications: Individual contraindications may not generalize across the class
Always consult the prescribing information for the specific medicine prescribed and discuss with your clinician.
Frequently asked questions
What are Intermediate-acting insulin (NPH)?
Intermediate-acting insulin (NPH) are medicines that share a common mechanism of action used for specific therapeutic indications. iMedic currently covers 8 substances in this class with detailed pages for each.
Are all Intermediate-acting insulin (NPH) interchangeable?
No. While medicines in the same class share a mechanism, they differ in potency, dosing, drug interactions, and tolerability. Switching between them is a clinical decision based on individual response, side effects, and treatment goals.
How do I choose between different Intermediate-acting insulin (NPH)?
Selection depends on the specific clinical indication, patient factors (age, comorbidities, kidney/liver function, other medications), tolerability of side effects, cost, and clinician preference. This is a prescribing decision.
Are Intermediate-acting insulin (NPH) available as generics?
Most well-established class members are available as generic alternatives, often substantially less expensive than brand-name versions while clinically equivalent. Newer members may still be brand-only.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.